The new SKYRIZI 150 mg pen incorporates wide grip handles, audible cues to help guide the administration process, and an indicator to signal when administration is complete.

Skyrizi® (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is now available in the US as a single-dose 150mg injection for the treatment of adults with moderate to severe plaque psoriasis. Previously administered as two 75mg injections per dose, Skyrizi 150mg is now administered with one injection per dose— via either a prefilled pen or syringe—every 12 weeks following two starter doses.

The new Skyrizi 150mg pen incorporates wide grip handles, audible cues to help guide the administration process, and an indicator to signal when administration is complete.

"We know many people living with psoriasis are looking for flexibility in how they manage their disease," says Patrick Horber, President, US Immunology, AbbVie, in a statement. "That's why we're proud to provide an updated SKYRIZI treatment experience that allows for fewer injections of the same SKYRIZI that patients and providers have come to know and trust." 

The FDA approved Skyrizi 150mg in April based on data from three clinical trials showing the single-dose Skyrizi 150mg injection was bioequivalent, working the same as two injections of Skyrizi 75mg per dose with a consistent efficacy and safety profile.

"Helping my psoriasis patients find an ideal treatment option for them requires not only assessment of the plaques on their skin, but consideration of a treatment experience that fits their lifestyle," says Lindsay Ackerman, MD, board-certified dermatologist and founder of Medical Dermatology Specialists in Phoenix, AZ, in a statement. "The single-dose injection options for SKYRIZI 150 mg allow for a maintenance treatment plan of only four injections per year and are a welcome addition to the psoriasis treatment mix." 

Skyrizi is part of a collaboration with Boehringer Ingelheim, with AbbVie leading development and commercialization of Skyrizi globally.